166
Participants
Start Date
September 18, 2013
Primary Completion Date
November 30, 2016
Study Completion Date
April 30, 2018
Trastuzumab Injectable Solution
Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
Trastuzumab Injectable Product
Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
Trastuzumab Injection
Powder for concentrate for solution for infusion. 1 cycle
Hospital Virgen del Puerto de Plasencia, Plasencia
Hospital Universitario Virgen de las Nieves, Granada
Hospital Universitario Arnau de Vilanova de Lleida, Lleida
Hospital Universitario Lucus Augusti, Lugo
Hospital Universitario La Princesa, Madrid
Hospital General Universitario Gregorio Marañón, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Univesitario Quirón Madrid, Pozuelo de Alarcón
Hospital Universitario Severo Ochoa, Leganés
Hospital Universitario de Fuenlabrada, Fuenlabrada
Hospital Costa del Sol, Marbella
Hospital Universitario Santa Lucía, Cartagena
Hospital Universitario de Salamanca, Salamanca
Hospital Universitario Virgen de la Macarena, Seville
Hospital Universitario Virgen del Rocío, Seville
Hospital Universitario San Joan de Reus, Reus
Hospital Virgen de la Salud, Toledo
Hospital Clínico Universitario de Valencia, Valencia
Hospital Universitario Miguel Servet, Zaragoza
Hospital de Manacor, Manacor
Hospital General Universitario de Granollers, Granollers
Hospital de Mataró, Mataró
Hospital Sant Joan Despí Moises Broggi, Sant Joan Despí
Hospital Nuestra Señora de Sonsoles, Ávila
Hospital del Mar, Barcelona
Hospital Clinic i Provincial, Barcelona
Hospital Germans Trias i Pujol, Barcelona
Spanish Breast Cancer Research Group
OTHER